Back to Atlas
CTransientStandard research/education caution
CMP-0293
Investigational
CagriSema
Obesity
Appetite suppression and weight loss
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Peptide combination
- Primary mechanism
- Amylin + GLP-1 agonism
- Primary market use
- Obesity
Pharmacology
- Molecular weight (Da)
- Combination / variable
- Oral bioavailability
- N/A
- Half-life
- Cagri ~6-8 d; sema ~7 d
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- Clinical
- Clinical status
- Investigational
- Value-for-money score
- 7 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Transient satiety pharmacology